The designed compounds demonstrated inhibitory activity against Bcl-2-expressing human cell lines, including breast cancer lines MCF-7 and MDA-MB-231 and A549 lung cancer cells at sub-micromolar concentrations, indicating their potency (Table 1, Figure 3). This evidence concerns the gene BCL2 and lung carcinoma.